Beta Therapeutic

Beta Therapeutics was an Australian private biotechnology company focused on developing disease-modifying therapeutics for inflammation-driven diseases and pathological tissue micro-environments. Its pipeline centered on small-molecule heparanase inhibitors and related heparanase-modulating compounds, with applications in ophthalmology, diabetes, inflammatory disease, and oncology. The company highlighted preclinical efficacy in mouse models and entered a strategic collaboration with Oxurion to develop heparanase inhibitors for dry age-related macular degeneration. Available market databases indicate the company was founded in 2011 in Canberra, Australia and later became inactive or out of business. Overall, Beta Therapeutics appears to have been a preclinical discovery-stage biotech built around extracellular matrix and inflammatory micro-environment biology.